Search
Gallium Ga-68 gozetotide
go.drugbank.com/drugs/DB16019ApprovedInvestigational[L27006] It is administered intravenously. … [A225396] Ga-68 PSMA-11 is an imaging agent that binds PSMA during positron emission tomography: it emits positrons to indicate the presence of PSMA-positive prostate cancer lesions in patients with suspected
Curcumin
go.drugbank.com/drugs/DB11672ApprovedInvestigationalIt is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities [A33166].
Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigational[A235169] As such, it has become a desirable target for PET imaging of prostate cancer tissues. … It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. The approval of...
TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64118] It is the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe.[L64118] … [L64095] It blocks neuromuscular transmission by cleaving SNAP-25, producing partial chemical denervation and a localized reduction in muscle activity.
Peginterferon beta-1a
go.drugbank.com/drugs/DB09122ApprovedInvestigationalIt was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. … [L31428] Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Fenfluramine
go.drugbank.com/drugs/DB00574ApprovedIllicitInvestigationalWithdrawnIt is currently sold under the name FINTEPLA® by Zogenix INC.[L14522] … It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression.
Novobiocin
go.drugbank.com/drugs/DB01051ApprovedInvestigationalVet approvedWithdrawnIt has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity.